GHRP-2: reference dosing schedule
> Updated:
Human schedule
GHRP-2 is given by subcutaneous injection. The figures below are a generalized reference to regimens described in studies and protocols for adults.
This is a concise reference to regimens described for adults; it is not an individual prescription.
GHRP-2 dosing in research protocols is set around a specific target (a growth-hormone pulse or another endpoint), so the GHRP-2 dosing schedule below is a reference point drawn from described regimens, not a standard for self-administration.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start | 100 mcg, once daily | Starting dose |
| Standard regimen | 100–200 mcg, 1–3x/day | Increase if needed |
| Maximum in this schedule | up to 300 mcg (≈1 mcg/kg) per injection, 2–3x/day | Maximum in this schedule |
Practical dosing and effect details
GHRP-2 belongs to the growth-hormone-releasing-peptide family and acts through the ghrelin receptor (GHS-R1a), triggering a short growth-hormone pulse within 15-30 minutes of administration. The effect is a pulse, not a sustained rise: the peptide's own blood concentration falls off much faster than the growth-hormone elevation it triggers, so one large daily dose reproduces the natural secretion rhythm poorly. The schedule on this page (100 mcg as the starting dose, up to 300 mcg at the upper limit, split across 1-3 administrations a day) reflects exactly that logic: several smaller doses through the day rather than one large one. Dose increases in the described protocols are usually tied to an observed response rather than applied blindly: sources describe this as titrating to the smallest dose that produces the expected effect, so a real protocol can stop at a lower step of the schedule. This is reference information for planning a research protocol, not a medical recommendation and not instructions for self-administration.
This reference is research-use material. The information is not medical advice and is not intended for diagnosis, treatment or prevention of disease.